|
USE OF MEDICAL RESOURCES
AND QUALITY OF LIFE OF PATIENTS WITH CHRONIC HEART FAILURE: A PROSPECTIVE SURVEY
IN A LARGE COMMUNITY HOSPITAL IN ITALY
*Maria
C. Albanese, MD, #°Michal Plewka MD, #Dario Gregori, PhD,
*Claudio Fresco, MD, +Giorgio Avon, MD, +Donato Caliandro,
MD, +Libero Grassi, MD, +Paolo Rossi, MD, +Paolo
Udina, MD, +Alessandro Bulfoni, MD, +Roberto Colle, MD, *#Paolo
M. Fioretti, MD, PhD, FESC
*Department
of Cardiology and +Departments of Internal Medicine, Santa Maria
della Misericordia Hospital and #IRCAB Foundation, Udine, Italy, °Department
of Cardiology, Medical University of Lodz, Poland.
Address
for correspondence:
Maria C. Albanese, MD
Department of Cardiology, Santa Maria della
Misericordia Hospital
P.le Santa Maria della
Misericordia, 15, 33-100 Udine, Italy
Tel. +39-432-552440 Fax +39-432-482353
E-mail:
ircab@mail.conecta.it
Abstract
Aims To assess the prevalence, clinical
characteristics, use of medical resources and quality of life in consecutive
patients with chronic heart failure (CHF) hospitalised in a large community
hospital during 3 months.
Methods and Results The study group
included 354 patients with CHF, admitted in the Departments of Internal Medicine
(97%) and Cardiology. Median age was 78 years [72;85], 45% were males. CHF was
the main diagnosis in 72%; 28% were in NYHA class III and 49% in class IV; 42%
had atrial fibrillation. Median hospital stay was 8 days [5;14], in-hospital
mortality 12%. Patients with CHF occupied 15% of the beds, 1330 ECG’s, 389
chest X-rays, 112 echocardiograms and 10 coronary angiograms were performed. A
quality of life questionnaire revealed that 82% had problems with mobility, 54%
with self-care, 88% with everyday activity. Thirty-nine percent of patients had
at least 1 hospitalisation during the previous year.
Conclusions Ninety-seven percent of
hospitalised patients with CHF are admitted in the Internal Medicine wards and
occupy 15% of beds. The majority of the patients are 72 years or older, with
severe heart failure. The frequency of rehospitalization(s) and mortality rate
in this population remains high. Echocardiography is performed only in 27% of
patients.
Key words: heart failure, health economics
Introduction
Chronic heart failure (CHF) is a major public health problem due to the
increasing incidence, the high costs of long-term drug treatment and the
frequent hospitalisations. Epidemiological data show an incidence in the general
population ranging from 1 to 5 new cases/1000/ year, increasing with age to more
than 30 new cases/1000/year among people over 75 years (1-5). Heart failure in
the elderly may by a different syndrome from that encountered in younger
population because of co-morbid disorders, interaction of multiple aetiologies,
concomitant medications, compliance and diagnostic difficulty (5). There are
many studies on CHF in Cardiology Departments, however a considerable number of
patients with CHF are managed in other hospital departments, mainly Internal
Medicine and there are few data describing those population (6-9).
The aim of the study was a in prospective survey on prevalence, clinical
characteristics, treatment, use of medical resources and quality of life in
patients hospitalised for CHF in a large community hospital.
Methods
The study group included consecutive patients with CHF hospitalised in Santa
Maria della Misericordia Hospital in Udine, Italy, in four Internal Medicine
Departments (total number of beds- 243) and in the Department of Cardiology (33
beds) during a 3 month period between march and may 1998. The diagnosis of CHF
was based on presence of at least two major or one major and two minor criteria
for heart failure, as previously described (10). Major criteria were: paroxysmal
nocturnal dyspnoea, orthopnoea, pulmonary congestion and presence of a third
heart sound. Minor criteria were: signs of peripheral venous congestion,
dyspnoea, and <400m walk without symptoms during normal daily activity.
A questionnaire (including clinical characteristics at admission, in-hospital
outcomes, co-morbidities, use of cardiological tests, nursing workload and
treatment at discharge) was developed for this study. The data were collected by
a dedicated nurse. In addition, patients were asked to answer a quality of life
questionnaire (EuroQol; including mobility, self-care, everyday activity, and
presence depression or anxiety) and a patient health score (1- the worse health
status, 10- the best health status) was collected as well (11).
A written informed consent was obtained from each patient.
Statistical
Methods
Extensive exploratory data analysis has been performed on the survey data.
Summary statistics for continuous variables were expressed as median values and
interquartile difference (first and third quartile). Categorical variables has
been analysed in terms of percentages. Significance has been based on a
non-parametric approach. In particular the Wilcoxon Rank Sum Test has been used
to detect difference among samples. The nominal level of significance has been
taken equal to 0.05. Missing values has been excluded from the analysis on a
pair-wise base. Computations has been performed in S-plus using the Hmisc and
Design libraries (12).
Results
During 3 months period 354 patients with CHF were hospitalised in the 5
hospital departments, 97% of them in the Departments of Internal Medicine.
Demographic and clinical characteristics of the study population at the
hospital admission are summarised in Table 1.
Median age was 78 years [72; 85], 55% were female. In 42% the aetiology of
CHF was ischemic, in 45% non-ischemic and in 13% unknown. Median heart rate was
95 bpm [80; 110], median systolic blood pressure 150 mmHg [124; 170] and median
diastolic blood pressure 90 mmHg [70; 90]. Atrial fibrillation was present in
42% of cases.
CHF was the primary diagnosis at admission in 72% of patients. Fifty percent
of patients were in New York Heart Association (NYHA) class IV, 28% in class III
and 22% in class I-II. The hospitalisation was urgent in 94% and elective in 6%.
Eighty nine percent of patients were admitted from home, 9% transferred from
another department and 2% from another hospital.
All patients had at least one co-morbidity (Table 2). The most common were
pulmonary diseases (32%).
Cardiological tests done during the hospital stay are summarised in Table 3.
ECG and chest X-ray were performed in the vast majority of patients (93% and
88%, respectively). Echocardiography was done during present survey in 94
patients (27%), and any echocardiography had been done before hospitalisation in
additional 10 patients. Median left ventricular ejection fraction (EF) was 44%
[30; 63]
In our group 39% of patients had at least 1 hospitalisation because of CHF
and 25% had more than one visit in the out-patient clinic during the previous
year.
During the survey, bed occupacy by patients with CHF was 3811 bed-days (15%
of the total bed occupacy)
Median length of hospital stay was 8 days [5; 14]. There were no significant
differences in length of stay between men and woman and patients with mild/
moderate and severe CHF. Eighty-two percent of patients were discharged from
hospital and 6% transferred to another department or hospital. In-hospital
mortality was 12% (42/354 patients), ranging from 1% (1/74 patients) in patients
in NYHA class I/II to 15% (41/276 patients) in class III/IV (p<0.01).
The nursing workload for the individual patients was small in 26%, medium in
49% and high in 22%. Patient’s and family’s education on discharge was made
in 88% by physicians and in 12% by nurses, the median time dedicated for this
was 3 minutes [1;10].
Pharmacological treatment on discharge is summarised in Table 4. Diuretics
were administered to 88% of the patients, ACE-inhibitors to 76%, digitalis to
65%, nitrates to 45%, anticoagulant therapy to 25% , amiodarone to 8% and
beta-blockers to 6%. No patients received calcium channel blockers. There were
no significant differences in treatment between male and female.
The results of the quality of life questionnaire are summarised in Table 5.
The questionnaire revealed that 82% of patients with heart failure had problems
with mobility, 54% with self-care, 88% with everyday activity, 80% had any kind
of pain and 78% were depressed or anxious. Health was described as worse than
one year before by 68% responders. Median patient health score (1- the worse
health status, 10- the best health status) was 5 points [3; 5]. There was no
significant difference in health score between men and women and between
patients in NYHA class I-II and class III-IV.
Discussion
The present study was undertaken to assess the prevalence, clinical
characteristics use of medical resources and quality of life in patients with
CHF treated in a large community hospital.
In the 3-month period 354 patients with CHF were admitted to the Santa Maria
della Misericordia Hospital in Udine. Ninety-seven percent of them were treated
in the Internal Medicine wards. Heart failure patients occupied 15% of beds in
Internal Medicine and Cardiology Departments (3811 bed- days). This is a useful
information for health providers, in order to quantify the size of the problem
related to heart failure patients not only for cardiological but also internal
medicine departments. Infact, the majority of the literature is dedicated to
patients admitted in the Cardiology Departments, while present data represent a
transmural, unselected hospital survey. Our data suggest, that what is seen in
most cardiology wards may only be the top of an iceberg.
Epidemiological studies show increasing incidence of CHF in the general
population following by growing number of hospital admission (1-5). In Sweden
there were about 10000 hospital admissions because of CHF during 1977, 14000
during 1981 and over 32000 during 1989. The admissions resulted in ca. 383000,
608000 and 1500000 days of hospital care, respectively (4). The incidence and
the prevalence of heart failure increased markedly with the age. In Italy the
prevalence of heart failure in consecutive patients admitted to geriatric
departments was 43% in those aged 65-74 and 58% in those over 85 years (13). It
has been also estimated that heart failure in Italy accounts for about 777000
days of cardiological bed occupation per year (10).
Clinical
characteristics
As previously mentioned, there is a gap between the clinical characteristics
of population studied in pharmacological trials and those seen in Cardiology
Departments (5,10). Our study showed that there is a further discrepancy between
patients admitted in the Cardiology and Medical Departments.
In our study the median age was 78 years and 75% of patients were older than
72 years, 55% were female, 78% were in NYHA class III and IV, but with
relatively well preserved left ventricular ejection fraction (EF >40% in 54%
of patients, median EF=44%). All patients in our group had at least one
co-morbidity.
Previous studies show that patients with CHF treated in Cardiology
Departments are generally younger (50-70 years) with higher proportion of males,
with advanced systolic dysfunction and generally without co- morbidities (5). In
the EARISA study - a recent registry of patients hospitalised in Cardiology
Departments in Italy- only 34% of 1089 patients with CHF were over 74 years
(14). In another Italian survey on 3921 patients (SEOSI) only 25% patients with
CHF hospitalised in Cardiology Departments were older than 75 years (10). Also
Reis al al (8) reported that internists take usually care of older patients than
cardiologists do (mean age 73 vs 69 years in Cardiology Department).
Further, we found that the majority of patients admitted in the Internal
Medicine Department had a severe CHF (50% in NYHA class IV and 28% in class
III). In contrast, the SEOSI study reported only 13% of patients in NYHA class
IV and 36% in class III in Cardiology Departments (10). Finally, the patients in
Internal Medicine departments in our group had more often atrial fibrillation
(42%) than the patients in Cardiology Departments in SEOSI study did (28%).
Treatment
According to the European Society of Cardiology (ESC) guidelines on the
treatment of heart failure (15) the therapeutic approach to systolic left
ventricular dysfunction in patients with CHF in the elderly (>75 years) is
identical to that in younger heart failure patients but should be applied more
cautiously and dosages adapted due to altered pharmacodynamic and
pharmacokinetic.
Following the guidelines diuretics are essential for symptomatic treatment
when fluid overload is present. In our study diuretics were given to 88% of
patients.
Cardiac glycosides are specifically indicated in patients with heart failure
and with atrial fibrillation with a fast ventricular rate, but also reduced the
need for hospitalisation relative to placebo (1,917 vs 2,039 hospitalisations,
respectively) in patients with heart failure and sinus rhythm (7). In our study
42% of patients had atrial fibrillation and 65% received digoxin.
The most proven therapy in heart failure is the treatment with angiotensin
converting enzyme (ACE) inhibitors (16-19), however despite the clear evidence
of clinical and economic effectiveness (20) there are data in literature that
ACE inhibitors are underused, especially in elderly patients (21). In a recently
published questionnaire (9) general practitioners (GP’s) reported more
frequent use of diuretic agent in mild and moderated CHF; internists were evenly
split between diuretics and ACE inhibitors and cardiologists were more likely to
use ACE- inhibitors. Cardiologists claimed a higher rate of prescribing three
drugs (ACE- inhibitor, diuretics and digoxin) in combination. Reis et al
reported that ACE- inhibitors are underused in patients with heart failure
hospitalised in medical departments compared to those treated by cardiologists-
respectively 46.1 % vs 57.1% of patients received ACE inhibitors at discharge
(8).
In our study ACE inhibitors were widely used (76% of patients). In patients
with mild and moderate (NYHA I-II) and severe (NYHA III-IV) heart failure the
percentage of ACE-inhibitors prescribed at discharge was similar, respectively
78% and 76%.
Several studies demonstrated benefits with b-blockers
therapy in patients with heart failure (22-24). Studies with b1
selective agents such metoprolol or bisoprolol revealed that those drugs
could reduce the risk of worsening heart failure. Recent studies have reported a
reduction in mortality and hospitalisation in patient with heart failure treated
with non-selective b-blocker carvedilol
(25). Heidenreich et al.(26) in a meta-analysis of randomised clinical trials
found that survival benefits of b-blockers
in patients with CHF was slightly higher for carvedilol than for another b-blockers, however the difference did not reach statistical
significance.
In the present study only 6% of patients were taking b-blockers. In patients in NYHA class I-II nine percent were
taking b-blockers, but in patients with
severe CHF, who encompassed 78% of our study group, only 3% were treated.
As well known, very important in the management of patients with CHF,
(especially old patients) is patients and family education about non-medical and
medical treatment. We would stress, that time dedicated for this in the present
study was extremely short (median- 3 minutes and in 75% of cases lower than 10
minuts).
Diagnostic
evaluation of patients with CHF
According to the Guidelines of the ESC echocardiography should be routinely
used for the optimal diagnosis of heart failure (27).
In the SEOSI study (10) echocardiography was the most frequently used
technique in patients with heart failure (73%) confirming that in Italian
Cardiology Departments ventricular function is preferentially assessed by
echocardiography. Edep et al. (9) found that the evaluation of left ventricular
function is performed by 92% of cardiologists, but only 69% of internists and
61% of GP’s. In another study only 34% of in-patients treated by generalists
underwent echocardiography (8). It was also reported (9) that GP’s and
internists use chest X- ray to establish diagnosis of CHF more often than
cardiologists (73% vs 68% vs 47% respectively), whereas cardiologists more
likely use an echocardiogram in making the initial diagnosis (48% vs 15% for
GP’s and 22% for internists). In our group chest-X ray was done in 88 % of
patients but any echocardiography only in 27% patients. This is probably due to
access problem to echo-equipment in Internal Medicine Department.
Coronary angiography was performed during the survey in 10 patients (3%). The
rate is lower than reported in Cardiology Departments in the EARISA (14) and the
SEOSI (10) study (11% and 7%, respectively), but in the SEOSI study the authors
reported all examinations done within the previous 3 months and also those
required according to the cardiologist at the visit (and no those done in the
reality).
In-hospital
clinical outcome
In the EARISA study the mean length of hospital stay for CHF was 5+/-5 days
(14); in another study (8) the mean length of stay was shorter in patients
hospitalised in medicine departments comparing to cardiology group (6.0 +- 5.3
days vs 6,9 +-4,7 days). In contrast, in our study the length of hospital stay
was longer- median 8 days [5;14]. In addition, the in-hospital all-cause
mortality was higher (12%) in our study than in the study of Reis et al (3,1%).
This is very likely due to more severe CHF at admission in our patients (78% in
NYHA class III and IV in our group and 43% in the study of Reis et al).
We found similar very high rehospitalisation rate for heart failure in our
hospital (39% of patients had had at least one hospitalisation in the previous
year) as Reis et al did ( 44%).
Quality
of life
In most clinical trails, the primary endpoint is mortality while quality of
life measurement is often neglected. In our study group a quality of life
questionnaire revealed that patients with heart failure had major general
problems, like mobility (82%), self-care (54%), everyday activity (88%), any
kind of pain (80%) and depression or anxiety (78%). Health was described as
better by only 2% responders, compared to the previous year. Health score (1-the
worst health status, 10- the best health status) was below 5 points in 75% of
patients.
Conclusions
Ninety-seven percent of patients with congestive heart failure hospitalised
in the large community hospital are admitted in the internal medicine wards and
occupy 15% of beds. The vast majority of the patients are 72 years or older,
with severe heart failure and very frequently one or more co-morbidities.
Despite adequate treatment (with the exception of underuse of beta-blockers) the
frequency of rehospitalization(s) and mortality rate in this population remains
high. The diagnosis is more often based on clinical examination, ECG and chest
X- ray than by more objective evaluation of heart function with echocardiography
(only 27% of patients had an echocardiography, probably due to access problem).
Quality of life questionnaire showed general disability in the great majority.
More studies are required to find the most cost-effective strategy for the
diagnosis and management of the increasing population with chronic heart
failure.
Dr M. Plewka was supported by a grant of the IRCAB Foundation, Udine, Italy.
Acknowledgments:
We would like to thank Mrs Luciana Giraldo for her assistance in the data
collection.
References
- Ho KL, Pinsky JL, Kannel WB, Levy D. The Epidemiology of Heart
Failure: The Framingham Study. J Am Coll Cardiol 1993; 22 [Suppl A]: 6A-
13A.
- Cowie MR, Mostterd A, Wood DA et al.The epidemiology of heart
failure. Eur Heart J 1997; 18: 202-225.
- Sinagra GF,
Perkan A, Zecchin M, Camerini F. L’epidemiologia dello scompenso cardiaco:
un problema crescente di sanita publica. G Ital Cardiol 1995; 25: 1043-1053.
- Andersson B, Waagstein F. Spectrum and outcome of congestive heart
failure in a hospitalized population. Am Heart J 1993; 126: 632- 640.
- Shape N, Doughty R. Epidemiology of heart failure and ventricular
dysfunction. Lancet 1998; 352 (suppl I): 1- 7.
- Harjai K, Boulos LM, Smart FW et al. Effects of caregiver
speciality on cost and clinical outcomes following hospitalization for heart
failure. Am J Cardiol 1998; 82: 82- 85.
- Philbin EF, DiSalvo TG. Influence of race and gender on care
process, resource use, and hospital based outcomes in congestive heart
failure. Am J Cardiol 1998; 82: 76- 81.
- Reis SE, Holubkov R., Edmundowicz D et al. Treatment of
patients admitted to the hospital with congestive heart failure:
speciality-related disparities in practice patterns and outcomes. J Am Coll
Cardiol 1997; 30: 733-738.
- Edep ME, Shah NB, Tateo IM, Massie BM. Differences between primary
care physicians and cardiologists in management of heart failure: Relation
to practice guidelines. J Am Coll Cardiol 1997; 30: 518- 526
- The SEOSI
Investigators. Survey on heart
failure in Italian hospital cardiology units. Results of the SEOSI study.
Eur Heart J; 18: 1457-1464
- The EuroQol Group. A new facility for the measurement of
health-related quality of life. Health Policy 1990; 16: 199-209.
- Alzola C, Harrel F. An introduction to S-plus and Hmisc and Design
libraries, 1997.
- Rengo F,
Acanfora D. Lo scompenso cardiaco nell’anziano. G Ital Cardiol 1994; 24:
1423- 1434.
- Schweiger C,
De Vita C, Langiano T et al. Studio sulla epidemiologia e
sull’assorbimento di risorse di ischemia, scompenso ed aritmie. G
Ital Cardiol 1997; 27 (suppl 2): 3- 54.
- The Treatment of Heart Failure. The task force of the Working Group
on Heart Failure of the European Society of Cardiology. Eur Heart J 1997;
18, 736-753
- CONSENSUS Trial Study Group. Effects of enalapril on mortality in
severe congestive heart failuire. Results of the north Scandinavian
enalapril survival study. N Engl J Med 1987; 316: 1429- 1435.
- The SOLVD Investigators. Effects of enalapril on mortality and the
development of heart failure in asymptomatic patients with reduced left
ventricular ejection fractions. N Engl J Med 1992; 327: 685- 691.
- The SOLVD Investigators: Effect of enalapril on survival in patients
with reduced left ventricular ejection fraction and congestive heart
failure. N Engl J Med 1991; 325; 293- 302
- Cohn J, Archibald D, Ziesche S et al. A comparison of
enalapril with hydralasine-isosorbide dinitrate in the treatment of chronic
congestive heart failure. N Engl J Med 1991; 325: 303- 310.
- Glick H, Cook J, Kinosian B, Pitt BP et al. Costs and effects
of enalapril theraphy in patients with symptomatic heart failure. An
economic analysis of the SOLVD treatment trial. J Cardiac Failure 1995; 1:
371- 380.
- Philbin E, Rocco T. Utility of angiotensin-converting enzyme
inhibitors in heart failure with preserved left ventricular systolic
function. Am Heart J 1997; 134: 188-195.
- Packer M. Do beta-blokers prolong survival in chronic heart failure?
A review of the experimental and clinical evidence. Eur Heart J 1998; 19 (suppl
B): B40- B46.
- Doughty RN, Rodgers A, Sharpe N MacMahon S. Effects of beta-blocker
therapy on mortality in patients with heart failure. A systematic overview
of randomized controlled trials. Eur Heart J 1997; 18: 560- 565.
- CIBIS Investigators and Committees. A randomized trial of
beta-blockade in Heart Failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS).
Circulation 1994; 90: 1765- 1773.
- Packer M, Bristow MR, Cohn JN et al., for the US Carvedilol
Heart Failure Study Group. The effect of carvedilol on morbidity and
mortality in patients with chronic heart failure. N Engl J Med 1996; 334:
1349- 1355.
- Heidenreich PA, Lee TT, Massie BM. Effect of beta-blockade on
mortality in patients with heart failure: A meta-analysis of randomized
clinical trials. J Am Coll Cardiol 1997; 30: 27- 34.
- Guidelines for the diagnosis of heart failure. The task force on
Heart Failure of the European Society of Cardiology. Eur Heart J 1995; 16,
741-751.
Table 1. Demographic and clinical
characteristics of the study population on admission to the hospital. Continuous
variables are expressed as median [first; third quartile] and categorical
variables as number of patients and percentage.
|
|
all patients (n =354)
|
|
Males
|
159 (45%)
|
|
Age (years)
|
78 [72;85]
|
|
NYHA class I
|
12 (3%)
|
|
NYHA class II
|
66 (19%)
|
|
NYHA class III
|
99 (28%)
|
|
NYHA class IV
|
177 (50%)
|
|
Heart rate (bpm)
|
96 [80;110]
|
|
Systolic blood pressure (mmHg)
|
150 [124;170]
|
|
Diastolic blood pressure (mmHg)
|
80 [70;90]
|
|
Left ventricular ejection fraction (% , n=105)
|
44 [30;63]
|
|
Sinus rhythm
|
191 (53%)
|
|
Atrial fibrillation
|
147 (42%)
|
|
Pacemaker rhythm
|
16 (5%)
|
|
Left bundle branch block
|
56 (16%)
|
Table 2. Prevalence of
co-morbidities (n=354)
|
|
nr (%) of
patients with co-
morbidity
|
|
Pulmonary
|
113 (32)
|
|
Diabetes mellitus
|
80 (23)
|
|
Vascular (non cardiac)
|
78 (22)
|
|
Infectious
|
34 (10)
|
|
Anemia
|
31 (9)
|
|
Metabolic
|
22 (6)
|
|
Endocrine (excl. diabetes)
|
10 (3)
|
|
Other
|
102 (29)
|
Table 3. Cardiological tests
performed during the survey (n=354).
|
|
nr (%) of pts with the test
|
total nr of tests
|
|
ECG
|
330 (93)
|
1330
|
|
Chest X-ray
|
277 (88)
|
389
|
|
Echocardiography
|
94 (27)
|
112
|
|
Coronary angiography
|
10 (3)
|
10
|
|
Holter ECG monitoring
|
10 (3)
|
12
|
|
Others
|
31 (9)
|
37
|
Table 4. Medication at discharge
(%)
|
|
all pts
n=354
|
NYHA I-II
n=78
|
NYHA III-IV
n=276
|
|
Diuretics
|
88
|
93
|
86
|
|
ACE-Inhibitors
|
76
|
78
|
76
|
|
Digitalis
|
65
|
65
|
66
|
|
Nitrates
|
45
|
43
|
47
|
|
Anticoagulants
|
25
|
16
|
28
|
|
Amiodarone
|
8
|
7
|
8
|
|
b-blockers
|
6
|
9
|
3
|
|
Ca-channel
blockers
|
0
|
0
|
0
|
Table 5. Quality of life (n=354).
|
Health aspect
|
Score
|
% of patients
|
|
Mobility
|
no problem
|
18
|
|
some problem
|
71
|
|
forced bed
|
11
|
|
Self-care
|
no problem
|
46
|
|
some problem
|
37
|
|
major problem
|
18
|
|
Everyday- activity
|
no problem
|
21
|
|
some problem
|
44
|
|
no activity
|
35
|
|
Any Pain
|
no pain
|
20
|
|
moderate
|
60
|
|
major
|
19
|
|
Depression or anxiety
|
no
|
22
|
|
moderate
|
50
|
|
major
|
28
|
|
Health now
|
better
|
2
|
|
same
|
30
|
|
worse
|
68
|
|